Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Deletions and/or loss of heterozygosity (LOH) on chromosome 15 (15q15 and 15q21) have been found in several human tumors, including carcinomas of the colorectum, breast, lung, prostate, and bladder, suggesting the presence of potential tumor suppressor gene(s) in this particular region of chromosome 15.
GCIP
also called CCNDBP1, DIP1, or HHM, localized at chromosome 15q15, is a recently identified helix-loop-helix leucine zipper (HLH-ZIP) protein without a basic region like the Id family of proteins. In this study, we reported that the expression of
GCIP
was significantly downregulated in several different human tumors, including breast tumor, prostate tumor, and colon tumors. In human colon tumors, both mRNA and protein expression levels of
GCIP
were decreased significantly compared to the normal tissues. Treatment of
colon cancer
cells SW480 with sodium butyrate (NaB), which induces
colon cancer
cell differentiation, can induce the upregulation of
GCIP
expression, suggesting that the protein functions as a negative regulator in cell proliferation. Overexpression of
GCIP
in SW480
colon cancer
cell line resulted in a significant inhibition on tumor cell colony formation, while silencing of
GCIP
expression by siRNA can promote cell colony formation. Furthermore, overexpression of
GCIP
inhibited the transcriptional activity of cyclin D1 promoter and the expression of cyclin D1 protein in the cell. Finally, we demonstrate that
GCIP
specifically interacts with one of the class III HDAC proteins, SirT6, which is important for maintaining genome stability. Together, our data suggest a possible function of
GCIP
in tumor suppression.
...
PMID:GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis. 1713 81
